At 19.8% CAGR, the North America Direct-to-Consumer Genetic Testing Market is Projected to be Worth US$ 3,041.12 million by 2030, Says Business Market Insights

According to Business Market Insights research, the North America Direct-to-Consumer genetic testing market was valued at US$ 716.40 in 2022 and is expected to reach US$ 3,041.12 million by 2030, registering a CAGR of 19.8% from 2022 to 2030. Growing interest in pharmacogenetics and increasing adoption of telehealth are among the critical factors attributed to the North America Direct-to-Consumer genetic testing market expansion. 

The Direct-to-Consumer genetic testing market will benefit from the increasing popularity of the pharmacogenetics field. A well-known application of gene-based personalization is pharmacogenetics, where genetic variations determine the selection of drug therapy that supports a company's growth. A comprehensive characterization of the genetic component underlying many complex diseases, traits, and drug responses has been enabled with the help of recent technological advances. This information has made genetic testing available more extensively in healthcare and can be used to assess the risk of inherited diseases and predict response to medications. Such tests can reduce drug-related adverse events, thereby increasing the effectiveness of drugs by the means of assessing the sensitivity of a person toward a particular drug. Pharmacogenetic testing is an interesting aspect for DTC companies because test results are actionable once a relevant drug is prescribed, which may be at the time of testing or many years later. Pharmacogenetic testing is one of the primary genetic testing services of DTC-GT companies. Pharmacogenetic testing reveals genetic variations associated with drug efficacy and responses. Therefore, most people are interested in finding out the function of their genome concerning their medication intake. DTC genetic testing companies such as 23andMe allow consumers to directly access their genetic information through an online service without the involvement of medical professionals.

A new model of DTC telemedicine is becoming increasingly popular. Patients select their clinical problem on a DTC company's website or mobile phone application and submit a medical intake form online. A doctor reviews this information and may or may not contact the patient for further information. According to an article titled "Comparison of Direct-to-Consumer Telemedicine Visits With Primary Care Visits" in the American Medical Association, DTC telemedicine companies completed more than 1 million care visits using this model in the past two years and have continued to experience growth throughout the COVID-19 pandemic. While COVID-19 testing has contributed to the rapid expansion of the Direct-to-Consumer diagnostic testing (DTC) market, DTC goes far beyond COVID-19 testing. This rapid transition to a digital workflow includes every step, from sample collection to analysis and archiving final results. Therefore, owing to the revolutionary technologies growing interest in pharmacogenetics, and rising adoption of telehealth, DTC genetic testing is becoming convenient, accessible, and effective, which is expected to boost the market growth in future.

On the contrary, high cost and privacy concerns associated with Direct-to-Consumer genetic testing hamper the growth North America Direct-to-Consumer genetic testing market .

Based on test type, the North America Direct-to-Consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing segment held 64.2% share of the North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 459.76 million. It is projected to garner US$ 1,893.21 million by 2030 to expand at 19.4% CAGR during 2022-2030.

By technology, the North America Direct-to-Consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held 68.4% share of North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 489.74 million. It is projected to garner US$ 2,138.37 million by 2030 to expand at 20.2% CAGR during 2022-2030.

Based on distribution channel, the North America Direct-to-Consumer genetic testing market is bifurcated into online and offline. The online segment held 65.5% share of North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 469.49 million. It is projected to garner US$ 2,018.59 million by 2030 to expand at 20.0% CAGR during 2022-2030.

Based on country, the North America Direct-to-Consumer genetic testing market is categorized into the US, Canada, and Mexico. The US held 83.4% share of North America Direct-to-Consumer genetic testing market in 2022, amassing US$ 597.47 million. It is projected to garner US$ 2,562.01 million by 2030 to expand at 20.0% CAGR during 2022-2030.

Key players operating in the North America Direct-to-Consumer genetic testing market are Ancestry Genomics Inc, Color Health Inc, Helix Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, Genetic Technologies Ltd, Gene by Gene Ltd, and Full Genomes Corp Inc, among others.

- In September 2023: 23andMe Holding Co. and the Sickle Cell 101, have joined forces to expand awareness of people's sickle cell carrier status. The collaboration will include DNA testing and access to 23andMe's Health + Ancestry Service for up to 1,000 eligible participants, and 23andMe will be providing monetary support to Sickle Cell 101 to support this effort.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com